Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
AVNR [NASD]
Avanir Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.47 Insider Own0.60% Shs Outstand171.83M Perf Week7.24%
Market Cap1.07B Forward P/E- EPS next Y-0.32 Insider Trans-7.20% Shs Float168.93M Perf Month19.39%
Income-71.80M PEG- EPS next Q-0.06 Inst Own73.70% Short Float9.67% Perf Quarter23.41%
Sales104.00M P/S10.28 EPS this Y-17.80% Inst Trans19.56% Short Ratio7.99 Perf Half Y49.52%
Book/sh0.40 P/B15.55 EPS next Y-10.30% ROA-84.50% Target Price8.73 Perf Year17.80%
Cash/sh0.49 P/C12.57 EPS next 5Y- ROE-235.50% 52W Range2.62 - 6.24 Perf YTD85.12%
Dividend- P/FCF- EPS past 5Y-14.40% ROI-149.40% 52W High-0.32% Beta1.16
Dividend %- Quick Ratio3.00 Sales past 5Y60.90% Gross Margin94.60% 52W Low137.40% ATR0.21
Employees267 Current Ratio3.10 Sales Q/Q44.40% Oper. Margin-65.60% RSI (14)66.62 Volatility3.80% 3.89%
OptionableYes Debt/Eq0.36 EPS Q/Q0.00% Profit Margin-68.90% Rel Volume0.78 Prev Close6.01
ShortableYes LT Debt/Eq0.19 EarningsAug 05 AMC Payout- Avg Volume2.05M Price6.22
Recom2.20 SMA2010.04% SMA5012.38% SMA20040.36% Volume1,599,240 Change3.49%
02-May-14Upgrade Mizuho Neutral → Buy $5 → $10
11-Dec-13Downgrade Mizuho Buy → Neutral $11 → $5
12-Jul-13Reiterated Mizuho Buy $10 → $11
08-Jul-13Reiterated Summer Street Research Buy $14 → $16
14-Jun-13Initiated Mizuho Buy $10
23-Aug-11Initiated JMP Securities Mkt Outperform $7
02-Nov-10Reiterated Wedbush Outperform $9 → $13
07-Oct-10Reiterated Canaccord Genuity Buy $6 → $9
01-Jul-10Initiated Jefferies Buy $10
29-Apr-10Initiated Wedbush Outperform $9
06-Apr-10Initiated Canaccord Adams Buy $6
06-Apr-10Initiated Canaccord Adams Buy
29-Jan-10Initiated Merriman Buy
01-Mar-07Reiterated Punk, Ziegel & Co Sell $2 → $1.25
27-Feb-07Upgrade Wedbush Morgan Sell → Hold $1.50
27-Aug-14 02:00PM  Avanir Doses First Patient with AVP-786, Updates on AVP-923 Zacks
26-Aug-14 09:00AM  Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder PR Newswire
08:54AM  Will Avanir (AVNR) Continue to Surge Higher? Zacks
21-Aug-14 03:47PM  5 companies that will benefit from ALS awareness at MarketWatch
15-Aug-14 01:04PM  AVANIR PHARMACEUTICALS, INC. Financials EDGAR Online Financials
14-Aug-14 09:58AM  Biodel Q3 Loss Narrower than Expected, Gives Pipeline Update Zacks
07-Aug-14 06:03AM  AVANIR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
06-Aug-14 03:10PM  Avanir's Q3 Loss in Line, Revenues Up on High Nuedexta Demand Zacks
05-Aug-14 04:30PM  Avanir Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:21PM  AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
04:01PM  Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update PR Newswire
01:30PM  Avanir Pharmaceuticals Inc Earnings Call scheduled for 1:30 pm ET today CCBN
08:30AM  Avanir Pharmaceuticals to Participate in Two Conferences in August PR Newswire
07:35AM  Avanir Pharmaceuticals Inc Earnings Call scheduled for 1:30 pm ET today CCBN
07:07AM  Q3 2014 Avanir Pharmaceuticals Earnings Release - After Market Close CCBN
28-Jul-14 08:30AM  Avanir Pharmaceuticals Announces Date of Fiscal 2014 Third Quarter Financial Results and Conference Call GlobeNewswire
21-Jul-14 09:15AM  Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder PR Newswire
16-Jul-14 09:00AM  Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study PR Newswire
11-Jul-14 07:00AM  3 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
09-Jul-14 10:40AM  Concert Pharmaceuticals' Shares Slip Despite Favorable FDA Meeting Zacks
30-Jun-14 07:22PM  Avanir Pharmaceuticals Announces Two Data Presentations Related to Pseudobulbar Affect (PBA) at the Alzheimer's Association International Conference (AAIC) PR Newswire
25-Jun-14 08:34AM  3 Health Care Stocks Under $10 to Trade for Breakouts
24-Jun-14 08:38AM  Avanir to present data related to safety and efficacy of AVP-825 at theflyonthewall.com
08:38AM  Avanir to present data related to safety and efficacy of AVP-825
08:30AM  Avanir Pharmaceuticals Announces Three Data Presentations Related to AVP-825 for the Acute Treatment of Migraine at the American Headache Society Annual Meeting PR Newswire
08:30AM  Avanir Pharmaceuticals Announces Three Data Presentations Related to AVP-825 for the Acute Treatment of Migraine at the American Headache Society Annual Meeting
12-Jun-14 11:10AM  Avanir Gains - AVP-825 Hits Phase III Primary Endpoint Zacks
11:10AM  Avanir Gains - AVP-825 Hits Phase III Primary Endpoint
10-Jun-14 04:00AM  Avanir Pharmaceuticals Announces Positive Outcome of Phase IIIb COMPASS Trial: A Head-to-Head Study Comparing AVP-825 to Oral Sumatriptan for the Acute Treatment of Migraine PR Newswire
04:00AM  Avanir Pharmaceuticals Announces Positive Outcome of Phase IIIb COMPASS Trial: A Head-to-Head Study Comparing AVP-825 to Oral Sumatriptan for the Acute Treatment of Migraine
03-Jun-14 06:34AM  Ignyta (RXDX) Jumps: Stock Adds 12.7% in Session Zacks
02-Jun-14 05:25PM  Patients Enrolled in Avanir Study Zacks
05:25PM  Patients Enrolled in Avanir Study
04:00PM  Pipeline Update from Avanir Zacks
04:00PM  Pipeline Update from Avanir
07:46AM  NPS Pharmaceuticals (NPSP) in Focus: Stock Rises 13.4% Zacks
07:46AM  NPS Pharmaceuticals (NPSP) in Focus: Stock Rises 13.4%
30-May-14 09:00AM  Avanir Pharmaceuticals Announces Multiple Data Presentations Related to Pseudobulbar Affect (PBA) Prevalence and Treatment at Two Conferences in June PR Newswire
09:00AM  Avanir Pharmaceuticals Announces Multiple Data Presentations Related to Pseudobulbar Affect (PBA) Prevalence and Treatment at Two Conferences in June
28-May-14 09:00AM  Avanir Pharmaceuticals to Participate in Two Conferences in June PR Newswire
09:00AM  Avanir Pharmaceuticals to Participate in Two Conferences in June
27-May-14 09:01AM  Avanir completes patient enrollment in study of AVP-923 at theflyonthewall.com
09:01AM  Avanir completes patient enrollment in study of AVP-923
09:00AM  Avanir Pharmaceuticals Announces Completion of Patient Enrollment in Study of AVP-923 for the Treatment of Agitation in Patients with Alzheimer's Disease PR Newswire
09:00AM  Avanir Pharmaceuticals Announces Completion of Patient Enrollment in Study of AVP-923 for the Treatment of Agitation in Patients with Alzheimer's Disease
15-May-14 10:06AM  Stock To Watch: AVANIR Pharmaceuticals (AVNR) In Perilous Reversal at TheStreet
10:06AM  Stock To Watch: AVANIR Pharmaceuticals (AVNR) In Perilous Reversal
07:53AM  Avanir (AVNR) Shares March Higher, Can It Continue? Zacks
03:42AM  Avanir Pharmaceuticals (AVNR) in Focus: Stock Moves 6.1% Higher Zacks
14-May-14 01:04PM  AVANIR PHARMACEUTICALS, INC. Financials EDGAR Online Financials +6.09%
07:21AM  QLT Inc. (QLTI) Falls: Stock Goes Down 9.13% Zacks
09-May-14 09:20AM  Avanir financial overhang removed, says JMP Securities at theflyonthewall.com +6.10%
08-May-14 04:00PM  Avanir Loss In Line with Ests, Revs Up Zacks
07-May-14 05:25PM  AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -6.72%
02:31PM  AVANIR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
06-May-14 09:39PM  Avanir Pharmaceuticals' (AVNR) CEO Keith Katkin on Q2 2014 Results - Earnings Call Transcript at Seeking Alpha
05:22PM  Avanir's Loss Narrows as Nuedexta Revenue Rises at Motley Fool
04:31PM  AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
04:30PM  Avanir Pharmaceuticals Earnings Call scheduled for 4:30 pm ET today CCBN
04:01PM  Avanir Pharmaceuticals Reports Fiscal 2014 Second Quarter Financial and Business Results PR Newswire
01:54PM  Avanir Pharmaceuticals: Shares Could Have Significant Upside Ahead at Seeking Alpha
07:34AM  Avanir Pharmaceuticals Earnings Call scheduled for 4:30 pm ET today CCBN
07:07AM  Q2 2014 Avanir Pharmaceuticals Earnings Release - After Market Close CCBN
05-May-14 04:31PM  AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
02-May-14 09:45AM  Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's "Dead Cat Bounce" Stock at TheStreet
09:37AM  Avanir Pharmaceuticals: Riding On A Non-Fundamental Catalyst at Seeking Alpha
06:21AM  Avanir Pharmaceuticals upgraded by Mizuho Briefing.com
01-May-14 04:08PM  Avanir Pharmaceuticals (AVNR) Stock Falls Off After Yesterday's Gain at TheStreet -6.63%
04:00PM  Avanir Pharmaceuticals to Participate in Two Conferences in May PR Newswire
03:41PM  Avanir Wins Lawsuit, Shares Up Zacks
06:40AM  Strength Seen in Avanir Pharmaceuticals, Inc. (AVNR) as Stock Shoots up 45.6% Zacks
30-Apr-14 05:27PM  On The Fly: Closing Wrap at theflyonthewall.com +45.61%
05:16PM  Why Avanir Pharmaceuticals, Pepco, and Level 3 Communications Are Today's 3 Best Stocks at Motley Fool
03:52PM  Salvation for Avanir in Patent Exclusivity 24/7 Wall St.
03:21PM  Why Avanir Pharmaceuticals (AVNR) Stock Spiked Today at TheStreet
03:04PM  Avanir Pharmaceuticals Prevails in NUEDEXTA Patent Trial Resulting in Exclusivity Through 2026 PR Newswire
29-Apr-14 09:00AM  Avanir Pharmaceuticals Announces Date of Fiscal 2014 Second Quarter Financial Results and Conference Call GlobeNewswire +7.55%
28-Apr-14 01:08PM  Obamacare Worries Subside as Orphan Drugs and Oncology Treatments Retain Pricing Power: A Wall Street Transcript Interview with Boris Peaker, Ph.D., Executive Director and Senior Analyst with Oppenheimer & Co. Covering the Biotechnology Sec Wall Street Transcript
08:30AM  Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System (CNS) Therapeutics Franchise at the 66th Annual Meeting of the American Academy of Neurology PR Newswire
27-Mar-14 04:20PM  Avanir's AVP-825 under FDA Review Zacks
26-Mar-14 09:00AM  Avanir Pharmaceuticals Announces Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine PR Newswire
21-Mar-14 06:31PM  Avanir Provides New Data Zacks
20-Mar-14 09:00AM  Avanir Pharmaceuticals Announces Publication of Research Showing Dextromethorphan has Antidepressant-like Effects In Vivo PR Newswire
19-Mar-14 04:33PM  AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
04:00PM  Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors PR Newswire
11:00AM  Impax, Par Pharmaceutical stayed from selling generic version of Avanir drug at theflyonthewall.com
09:40AM  Avanir Pharmaceuticals Presents Data from a Benchmark Study of PBA Symptoms in Veterans with Mild Traumatic Brain Injury PR Newswire
06-Mar-14 06:07PM  Nasdaq stocks posting largest percentage increases AP -11.00%
01:30PM  Nasdaq stocks posting largest percentage increases AP
07:44AM  Avanir (AVNR) Catches Eye: Stock Soars 16.3% Zacks
07:44AM  Avanir (AVNR) Catches Eye: Stock Soars 16.3%
05-Mar-14 06:02PM  Nasdaq stocks posting largest percentage increases AP +16.28%
28-Feb-14 09:00AM  Avanir Pharmaceuticals to Participate in Two Conferences in March PR Newswire
27-Feb-14 07:15AM  Avanir Pharmaceuticals (AVNR) Jumps: Stock Moves 11.7% Higher Zacks
07:15AM  Avanir Pharmaceuticals (AVNR) Jumps: Stock Moves 11.7% Higher
26-Feb-14 01:21PM  Traders bet on comeback in Avanir optionMONSTER +11.72%
01:21PM  Traders bet on comeback in Avanir
21-Feb-14 08:01AM  Avanir Pharmaceuticals Inc.: What Investors Must Watch in 2014 at Motley Fool
19-Feb-14 04:16PM  AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Sub EDGAR Online
14-Feb-14 01:37PM  Will Mallinckrodt's Xartemis Change How We Treat Pain? at Motley Fool
Avanir Pharmaceuticals, Inc., together with its subsidiaries, is engaged in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. It primarily offers NUEDEXTA, a dual N-methyl-D-aspartate receptor antagonist and sigma-1 agonist for the treatment of pseudobulbar affect; and Docosanol 10% cream, an over-the-counter product for the treatment of cold sores. The company's clinical development stage products comprise AVP-923, which has completed Phase II clinical trials for the treatment of central neuropathic pain in patients with multiple sclerosis; is in Phase II clinical trials for the treatment of agitation in patients with Alzheimer's disease; and is in Phase II clinical trials for the treatment of levodopa-induced-dyskinesia in Parkinson's disease, as well as completed Phase III trials for the treatment of patients with diabetic peripheral neuropathic pain. It is also developing AVP-786, a Phase I clinical trial novel investigational drug product for the treatment of neurologic and psychiatric disorders; and AVP-825, an investigational drug-device combination product, which is in Phase III clinical trials, to treat acute migraine. The company has a license agreement with Concert Pharmaceuticals, Inc. to develop and commercialize deuterium-modified dextromethorphan for the potential treatment of neurologic and psychiatric disorders, as well as rights to other deuterium-modified dextromethorphan compounds; and a license agreement with OptiNose AS for the development and commercialization of a novel breath powered intranasal delivery system to treat acute migraine. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OCAMPO CHRISTINEVice President, FinanceAug 26Sale6.102,11012,87179,871Aug 28 09:03 PM
Katkin KeithPresident and CEOAug 01Sale5.269,67050,864760,412Aug 01 08:44 PM
Katkin KeithPresident and CEOMay 28Sale5.01442,2122,215,482750,082May 30 08:00 PM
OCAMPO CHRISTINEVice President, FinanceMay 16Sale4.8811,90058,0723,000May 16 08:00 PM
OCAMPO CHRISTINEVice President, FinanceMay 14Sale5.1325,596131,30781,981May 16 08:00 PM
Siffert Joao MDSVP, R&DDec 18Sale2.635,97015,713110,230Dec 20 05:32 PM
OCAMPO CHRISTINEVice President, FinanceDec 18Sale2.632,4506,44563,202Dec 20 05:26 PM
Katkin KeithPresident and CEODec 18Sale2.6729,51578,935445,707Dec 20 05:24 PM
PALEKAR ROHANSVP & Chief Commercial OfficerDec 17Buy2.8010,00028,000143,000Dec 19 04:31 PM
PALEKAR ROHANSVP & Chief Commercial OfficerNov 04Buy4.1910,00041,895133,000Nov 05 08:01 PM
Katkin KeithPresident and CEONov 01Sale4.144,38518,138475,222Nov 05 08:00 PM
Siffert Joao MDSVP, R&DSep 18Option Exercise1.8521,09439,024137,294Sep 19 08:50 PM
Siffert Joao MDSVP, R&DSep 18Sale4.2221,09488,968116,200Sep 19 08:50 PM